Special Issue "Clinical Trends and Therapies of the COVID-19 Pandemic"
Deadline for manuscript submissions: 31 August 2021.
Interests: infectious diseases; emerging and remerging infectious diseases; tropical sisease; virology; pharmaco epidemiology; clinical trials
The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 in Wuhan, China.
Since then, research has come a long way, but several areas are still poorly defined. In particular, there are still significant uncertainties about the primary natural reservoir of the ancestor of the coronavirus strain that eventually produced the human spillover. In addition, the transmission of SARS-CoV-2 among human beings has produced novel epidemic scenarios whose local evolutions are still poorly understood.
Although the pandemic is spreading globally, the subsequent waves of the epidemic have been uneven across the geographic areas and different population groups. Indeed, current predictive models are still too weak to produce a reliable estimation about the role of several pivotal factors associated with the intensity of the epidemic and with the case–fatality rate of the diseases.
Moreover, while old medical practices have already been revised to optimize COVID-19 therapy by using current tools (e.g., steroids, heparin and oxygen therapy), the breathtaking efforts in the field of drug research and development is finally starting to bear fruit.
In the upcoming year, several new compounds will be licensed, including new vaccines, monoclonal antibodies against SARS-CoV-2, new antivirals and potentially a series of refurbished immune modulants.
The clinical impact of these all these new strategies is the primary objective of this Special Issue.
Dr. Emanuele Nicastri
Dr. Simone Lanini
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- monoclonal antibody
- clinical trials
- longitudinal Cohort